A team from the University of Missouri has created a potential delivery system that uses an extract from tea leaves to target radioactive gold nanoparticles directly to prostate tumors.
Researchers from the U.K. and Spain have used gold nanostars to create an ultrasensitive test for biomarkers.
Beckman Coulter has received premarket approval from the FDA for its biomarker-based Prostate Health Index (phi). According to the company, this test is 2.5 times more specific in detecting prostate cancer than PSA (prostate-specific antigen) tests in men with raised levels of PSA, and could cut the number of unnecessary prostate biopsies 31%.
Radiotherapy is commonly used in the treatment of prostate cancer, and immunotherapy company Advaxis has seen some promising preclinical results when it combined its prostate cancer vaccine, ADXS-PSA (ADXS31-142), with a dose of radiation, in a study published in Cancer Immunology Immunotherapy.
Prostate cancer could affect as many as one in 6 men during their lifetime, according to the U.S. National Cancer Institute, and for some their cancers recur and become hormone-resistant. The Cancer Institute of New Jersey and the National Cancer Institute have hooked up to see if combining a vaccine and hormone treatment will improve the response.
Gold has been used in medicine since 2500 BC, as a drug and in medical devices, but since the 1980s, it's gained a starring role in diagnostics. In a paper in Nature Materials, its latest incarnation is as gold nanostars helping to create a very sensitive biomarker-driven biosensor for spotting disease in its very early stages.
RalA and RalB are nasty proteins whose mere presence seems to generate massive amounts of cellular trouble leading to aggressive versions of prostate, bladder and skin cancer, University of Colorado Cancer Center researchers have found.
Researchers at the University of Pittsburgh School of Medicine have spotted copy number variations or CNVs, duplications or deletions in stretches of the genetic material, that could help doctors predict what prostate cancers might do after diagnosis.
This form of prostate cancer seems to run in families, including families in which women have had breast cancer linked with the BRCA1 mutation.
According to the U.K.'s The Telegraph, Bavarian Nordic's Prostvac prostate cancer vaccine has started a Phase III clinical trial in the U.K.